Cencora Inc.
$ 320.82
-0.51%
10 Apr - close price
- Market Cap 62,728,364,000 USD
- Current Price $ 320.82
- High / Low $ 322.78 / 314.51
- Stock P/E 38.76
- Book Value 9.81
- EPS 8.32
- Next Earning Report 2026-05-06
- Dividend Per Share $2.25
- Dividend Yield 0.69 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 1.34 %
- 52 Week High 376.92
- 52 Week Low 269.07
About
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Analyst Target Price
$402.92
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-02 | 2023-08-02 | 2023-05-02 |
| Reported EPS | 2.87 | 3.84 | 4 | 4.42 | 3.73 | 3.34 | 3.34 | 3.8 | 3.28 | 2.86 | 2.92 | 3.5 |
| Estimated EPS | 3.39 | 3.79 | 3.84 | 4.1 | 3.52 | 3.22 | 3.22 | 3.69 | 2.89 | 2.81 | 2.83 | 3.3 |
| Surprise | -0.52 | 0.05 | 0.16 | 0.32 | 0.21 | 0.12 | 0.12 | 0.11 | 0.39 | 0.05 | 0.09 | 0.2 |
| Surprise Percentage | -15.3392% | 1.3193% | 4.1667% | 7.8049% | 5.9659% | 3.7267% | 3.7267% | 2.981% | 13.4948% | 1.7794% | 3.1802% | 6.0606% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 4.83 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-02 | 2025-12-01 | 2025-09-03 | 2025-06-02 | 2025-03-03 | 2024-11-29 | 2024-08-26 | 2024-05-24 | 2024-02-26 | 2023-11-27 |
| Amount | $0.6 | $0.6 | $0.55 | $0.55 | $0.55 | $0.55 | $0.51 | $0.51 | $0.51 | $0.51 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COR
2026-04-10 05:07:23
Cencora (COR) has experienced recent share price weakness, with an 8% decline over the past month, though its long-term performance remains strong. Despite being considered 20.9% undervalued by a narrative fair value model, its current P/E ratio of 38.6x is significantly higher than its peers and a fair ratio, suggesting a premium valuation. Investors need to weigh the potential for future growth driven by digital infrastructure against risks like tighter drug pricing regulations and potential P/E compression.
2026-04-10 05:07:14
Cencora (COR) has seen an 8% decline in share price over the past month, but a strong 185.60% return over five years. While a narrative fair value suggests it's 20.9% undervalued due to digital investments, its P/E ratio of 38.6x is higher than peers, prompting a need to weigh risks like drug pricing regulations against future growth. Investors should consider both the potential upside and the premium currently being paid for the stock.
2026-04-08 16:45:00
Cencora Inc. (COR) shares rose 1.26% on Wednesday, closing at $324.93, snapping a two-day losing streak. Despite the increase, the stock underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average saw larger gains of 2.51% and 2.85%, respectively.
2026-04-08 14:37:26
Evercore ISI has adjusted its price target for Cencora (COR) to $360 from $420, while maintaining an "Outperform" rating on the stock. Cencora, Inc. specializes in distributing pharmaceutical products and offers services to healthcare providers and patients in the United States and Canada. This news follows several other recent updates for the company, including an acquisition of EyeSouth Partners' Retina Business and the announcement of their CFO's retirement.
2026-04-08 08:40:27
This article analyzes Cencora's (COR) valuation using two methods: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio. The DCF model suggests Cencora is undervalued by 46.6% with an intrinsic value of $601.42 per share, while its current P/E of 38.41x is above the estimated fair ratio of 33.90x, indicating it is overvalued by that metric. The piece also discusses market narratives that offer different perspectives on the stock's fair value.
2026-04-08 08:37:25
This article analyzes Cencora's (COR) valuation amidst recent healthcare supply chain scrutiny. Using a Discounted Cash Flow (DCF) model, the stock appears significantly undervalued at a 46.6% discount, while a Price-to-Earnings (P/E) ratio comparison suggests it is overvalued. The article highlights the conflicting valuations and encourages investors to consider different narratives and risk factors.
